Nasal Administration of Recombinant Osteopontin Attenuates Early Brain Injury After Subarachnoid Hemorrhage | Zendy

Basak Caner Topkoru | Zendy; Orhan Altay | Zendy; Kamil Ďuriš | Zendy; Paul R. Krafft | Zendy; Junhao Yan | Zendy; John H. Zhang | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Nasal Administration of Recombinant Osteopontin Attenuates Early Brain Injury After Subarachnoid Hemorrhage

Author(s) -

Basak Caner Topkoru,

Orhan Altay,

Kamil Ďuriš,

Paul R. Krafft,

Junhao Yan,

John H. Zhang

Publication year - 2013

Publication title -

stroke

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.397

H-Index - 319

eISSN - 1524-4628

pISSN - 0039-2499

DOI - 10.1161/strokeaha.113.001574

Subject(s) - wortmannin , medicine , subarachnoid hemorrhage , neuroprotection , protein kinase b , pharmacology , perforation , pi3k/akt/mtor pathway , apoptosis , pathology , anesthesia , biology , biochemistry , materials science , metallurgy , punching

Neuronal apoptosis is a key pathological process in subarachnoid hemorrhage (SAH)-induced early brain injury. Given that recombinant osteopontin (rOPN), a promising neuroprotectant, cannot pass through the blood-brain barrier, we aimed to examine whether nasal administration of rOPN prevents neuronal apoptosis after experimental SAH.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research